Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD))
NCT ID: NCT01993628
Last Updated: 2013-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2013-10-31
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Constructional apraxia has been described in both disease.The underlying mechanisms have been less studied and could be different in AD and LBD.
The definition of the constructional apraxia is purely descriptive and few models are inconclusive.
It is admitted that drawing tasks involve visuo-perceptive and visuo-spatial abilities, executive functions and working memory as well as purely "constructive" skills.
Regarding to different studies, visuo-perceptive abilities are more severely impaired in LBD than in AD and are considered as an early onset sign of the disease.
Executive functions deficits are documented in AD and LDB and could contribute to the drawing impairment.
It is possible to compensate the planning disorders in giving patient the best strategy to use.
If drawing impairment persists, they should result of others mechanisms like visuo-perception, visuo-spatial or constructive deficits.
The investigators suggest that giving the best planning strategy will help more AD patients who are supposed to fail in raison of an executive impairment, than the LDB group who is supposed to present visuo-perceptive deficits. An MRI will be proposed to study the cerebral areas involved in constructional apraxia.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alzheimer's disease (AD)
Rey figure test and MRI
Rey figure test
MRI
Lewy body's dementia (LBD)
Rey figure test and MRI
Rey figure test
MRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rey figure test
MRI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 45 years
* the cognitive impairment is mild to moderate
* French speaker
* a caregiver is present
* An informed consent is signed by the patient and the p.i.
Exclusion Criteria
* Other neurological disease (FTD, brain tumor, vascular disease…)
* Psychiatric disease (Schizophrenia, major depression, psychotic disorders, melancholia…)
* Patient who doesn't want to be informed in case of the discovery of an abnormality
* View or audition deficits, or motor disability which can interfere with the cognitive testing
* Patient participating to an exclusive protocol or in the period of exclusion
* Pregnant woman
* Person under an administrative or legal measure of liberty privation
* Person under a legal measure of protection or under administrative supervision
* Person unable to give his consent
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xavier De Pétigny, Docteur
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5565
Identifier Type: -
Identifier Source: org_study_id